@article { , title = {Editorial: One Health and Veterinary Regenerative Medicine: Translational Applications}, abstract = {Editorial on the Research Topic One Health and Veterinary Regenerative Medicine: Translational Applications Regenerative Medicine has been heralded as having the potential to provide much needed treatments for many significant diseases in human and veterinary medicine (1). However, the restorative/regenerative potential for these therapies has yet to be fully achieved. Recent years and the current pandemic have brought attention to some challenges in regenerative medicine as well as the benefits of interdisciplinary collaborations and One Health approaches that recognize the close connection between the health of people and animals. Veterinary medicine and naturally occurring diseases in animals can provide impactful information and help direct and refine new treatments and prevention strategies for the betterment of both human and animal health and the environment. A thorough assessment of the current strengths, gaps, and priorities in veterinary and human regenerative medicine can help identify critical steps to accelerate the progress and impact of regenerative therapies. With this Research Topic, we seek to highlight the current state of veterinary regenerative medicine, with an emphasis on One Health and translation of novel therapies to the clinic, as a means of encouraging collaboration and a call to action on areas of need. We identified five focus areas for the Research Topic: (1) regulatory topics, differences, and hurdles; (2) safety and efficacy issues; (3) challenges in veterinary clinical studies, including study quality and ethical discussions; (4) current naturally occurring animal models; and (5) sustainability in regenerative medicine. Regulation of regenerative medicine, with its many novel and diverse products, has been an important and evolving area of discussion (2). Getting safe and effective regenerative therapies tested, manufactured, and to market involves development of new collaborations, terminology, protocols, and procedures and close attention to detail. Specific topics range from the current state of regulation in veterinary regenerative medicine, including comparisons between veterinary species, human regenerative medicine, and regulatory agencies, to advocating for transparency in study methods and sound, well-powered experimental designs with appropriate control groups, blinding, and randomization. One of the six papers included in this Research Topic discusses challenges and recommendations in manufacturing mesenchymal stromal cells (MSC) for the treatment of osteoarthritis in canine patients. Ivanovska et al. highlight critical issues to be addressed in MSC products for veterinary use. They provide recommendations based on standards and strategies applied in human MSC manufacturing to facilitate the development of quality standards that will contribute to the standardization of cell manufacturing methods and improved quality assurance across the field.}, doi = {10.3389/fvets.2022.959564}, journal = {Frontiers in Veterinary Science | www.frontiersin.org}, note = {Specialty section: This article was submitted to Veterinary Regenerative Medicine, a section of the journal Frontiers in Veterinary Science Received: 01 June 2022 Accepted: 20 June 2022; EDITORIAL Edited and reviewed by: *Correspondence: Tracy L. Webb Tracy.Webb@colostate.edu † These authors have contributed equally to this work Citation: Webb TL, Spaas JH and Guest DJ (2022) Editorial: One Health and Veterinary Regenerative Medicine: Translational Applications. Front. Vet. Sci. 9:959564.}, pages = {-}, publicationstatus = {Published}, publisher = {Frontiers Media}, volume = {1}, keyword = {Comparative Physiology and Clinical Science, regenerative medicine, one health, translational, veterinary, clinical studies, naturally occurring}, year = {2022}, author = {Webb, Tracy L and Spaas, Jan H and Guest, Debbie J} }